Anteris Technologies Global Corp. Launches IPO Roadshow

Anteris Technologies Global Corp. ("ATGC") announced the launch of a roadshow for its proposed initial public offering (IPO) of 14,800,000 shares of common stock in the U.S. (the "Offering"). All shares will be offered by ATGC, which also intends to grant underwriters a 30-day option to purchase up to an additional 2,220,000 shares at the IPO price, minus underwriting discounts and commissions. The company has applied to list its common stock on the Nasdaq Global Market under the ticker symbol "AVR."

ATGC plans to utilize the net proceeds from the Offering, together with existing cash, primarily for the continued development of its DurAVR® transcatheter heart valve ("DurAVR® THV") and for preparing a global pivotal study for treating severe aortic stenosis. Remaining proceeds will be allocated to working capital and other corporate purposes, including repayment under its convertible note facility. TD Cowen, Barclays, and Cantor are joint book-running managers for the Offering, with Lake Street Capital Markets acting as the lead manager.

Post-Offering, ATGC aims to list its CHESS Depositary Interests ("CDIs") on the Australian Securities Exchange ("ASX") under the symbol "AVR."

The Offering will only be made through a prospectus. Preliminary prospectus copies may be obtained from:
– TD Securities (USA) LLC: 1 Vanderbilt Avenue, New York, NY 10017, Phone: (855) 495-9846, Email: TD.ECM_Prospectus@tdsecurities.com
– Barclays Capital Inc.: 1155 Long Island Avenue Edgewood, NY 11717, Phone: (888) 603-5847, Email: Barclaysprospectus@broadridge.com
– Cantor Fitzgerald & Co.: 110 East 59th Street, 6th Floor, New York, NY 10022, Phone: (212) 915-1800, Email: prospectus@cantor.com

A registration statement on Form S-1 relating to the common stock has been filed with the Securities and Exchange Commission and is pending effectiveness. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release is for information purposes only and does not constitute an offer to sell any securities.

About ATGC

ATGC was incorporated on January 29, 2024, to reorganize the operations of Anteris Technologies Ltd ("Anteris"), an Australian company listed on the ASX, into a Delaware corporation.

About Anteris Technologies Ltd (AVR)

Anteris Technologies Ltd (AVR) is dedicated to developing innovative medical devices for structural heart disease. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris creates solutions like its lead product, DurAVR®, a bioengineered transcatheter heart valve for treating aortic stenosis.

DurAVR® is unique for being the first valve of its kind to use a single piece of bioengineered tissue. Made with ADAPT® tissue, Anteris’ patented anti-calcification technology, the valve has been clinically used for over 10 years and has been distributed to over 55,000 patients worldwide. The ComASUR® Delivery System ensures precise valve placement with balloon-expandable delivery for ideal alignment with the heart's native commissures.